Alphabet’s AI drug unit Isomorphic Labs raises $600 mn from OpenAI backer

Isomorphic Labs, the Alphabet Inc.-owned company that uses artificial intelligence to discover drugs, has raised $600 million, the first time it’s taken in external funding.

The round was led by Thrive Capital, with participation from Alphabet and its venture arm, GV, Isomorphic Labs said in a statement Monday. The company’s valuation was not disclosed. Thrive has also invested in OpenAI, a rival to Alphabet’s Google in researching artificial intelligence and bringing to market user-facing products such as chatbots.